Scarica l'app Stockscreener
28.07
2.37%
-0.68
Pre-mercato:
27.69
-0.38
-1.35%
Precedente Chiudi:
$28.75
Aprire:
$28.26
Volume 24 ore:
382.45K
Relative Volume:
2.82
Capitalizzazione di mercato:
$1.24B
Reddito:
-
Utile/perdita netta:
-
Rapporto P/E:
-
EPS:
-
Flusso di cassa netto:
-
1 W Prestazione:
-2.09%
1M Prestazione:
-5.93%
6M Prestazione:
+0.00%
1 anno Prestazione:
+0.00%
Intervallo 1D:
$28.00
$29.78
Intervallo di 1 settimana:
$26.02
$32.19
Portata 52W:
$24.15
$32.23
Avalyn Pharma Inc Stock (AVLN) Company Profile
Nome
Avalyn Pharma Inc
Settore
Industria
Telefono
(206) 707-0340
Indirizzo
105 W FIRST ST., BOSTON
Compare AVLN vs VRTX, REGN, ARGX, ALNY, RVMD
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
AVLN
Avalyn Pharma Inc
|
28.07 | 1.27B | 0 | 0 | 0 | 0.00 |
VRTX
Vertex Pharmaceuticals Inc
|
453.17 | 114.33B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
614.73 | 64.47B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
878.49 | 54.99B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
281.90 | 38.42B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
156.58 | 34.03B | 742.00K | -1.37B | -1.07B | -7.0731 |
Avalyn Pharma Inc Borsa (AVLN) Ultime notizie
IPO Tracker 2026: Kardigan stitches up $369M IPO plan - BioSpace
Avalyn Pharma (AVLN) Earnings Date and Reports 2026 - MarketBeat
Avalyn Pharma Inc.common stock (AVLN) Stock Price, News, Quote & History - FinancialContent
Avalyn Pharma Outlines Inhaled Fibrosis Push After IPO, With Pivotal Data Ahead - inkl
Morgan Stanley Maintains AVALYN PHARMA INC(AVLN.US) With Buy Rating, Maintains Target Price $53 - 富途牛牛
Avalyn Pharma Inc. 2026 Q1 Financial Report and Material Risks Overview - Minichart
Avalyn Pharma 1Q Loss $26.9M >AVLN - Moomoo
AVLN SWOT Analysis: Financial Challenges and Growth Potential Re - GuruFocus
Avalyn Pharma (AVLN) Stock Trends and Sentiment 2026 - MarketBeat
Avalyn Pharma Inc. 1Q 2026: Net income $(26.9M), EPS $(21.83) — 10-Q Summary - TradingView
Avalyn: Q1 Earnings Snapshot - marketscreener.com
AVLN: Q1 2026 net loss widened to $26.9M; IPO proceeds extend cash runway into 2029, but more funding needed - TradingView
Avalyn Pharma (Nasdaq: AVLN) widens Q1 loss but extends cash runway into 2029 - Stock Titan
Avalyn Reports First Quarter 2026 Financial Results and Recent Business Highlights - The Manila Times
Avalyn Pharma (AVLN) Stock Chart and Price History 2026 - MarketBeat
Avalyn Pharma (AVLN) Stock Analysis Report | Financials & Insights - Benzinga
Assessing Avalyn Pharma (AVLN) Valuation As Investors React To Recent Share Price Moves - Yahoo Finance
Top Avalyn Pharma (AVLN) Competitors 2026 - MarketBeat
Avalyn Pharma Inc. (AVLN) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Avalyn Pharma Inc.: Target Price Consensus and Analysts Recommendations | AVLN | US05348Y1055 - marketscreener.com
Avalyn to Participate in the Jefferies Global Healthcare Conference - GlobeNewswire
AVLN Initiated Coverage by Morgan Stanley -- Price Target Set at $53 - GuruFocus
AVLN Initiates Coverage by Guggenheim -- Price Target Announced at $80 - GuruFocus
This Lear Analyst Turns Bullish; Here Are Top 4 Upgrades For Tuesday - Benzinga
Jefferies Maintains AVALYN PHARMA INC(AVLN.US) With Buy Rating, Maintains Target Price $52 - 富途牛牛
This Avalyn Pharma Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday - Benzinga
Guggenheim Initiates Avalyn Pharma at Buy With $80 Price Target - Moomoo
Morgan Stanley Initiates AVALYN PHARMA INC(AVLN.US) With Buy Rating, Announces Target Price $53 - Moomoo
Jefferies Initiates Avalyn Pharma at Buy With $52 Price Target - Moomoo
Morgan Stanley initiates Avalyn Pharma stock coverage with overweight rating By Investing.com - Investing.com South Africa
Morgan Stanley initiates Avalyn Pharma stock coverage with overweight rating - Investing.com Australia
Avalyn Pharma (AVLN) Stock Forecast and Price Target 2026 - MarketBeat
Jefferies initiates Avalyn Pharma stock with buy on lung disease data - Investing.com India
Guggenheim initiates Avalyn Pharma stock with buy rating on fibrosis drugs By Investing.com - Investing.com Australia
Guggenheim initiates Avalyn Pharma stock with buy rating on fibrosis drugs - Investing.com UK
Jefferies Initiates AVALYN PHARMA INC(AVLN.US) With Buy Rating, Announces Target Price $52 - Moomoo
AVLN Stock News Today | Earnings, Events & Price Alerts - Intellectia AI
AVLN Technical Analysis | Trend, Signals & Chart Patterns | AVALYN PHARMA INC (NASDAQ:AVLN) - ChartMill
Avalyn Pharma to present 4-year AP01 data at EULAR conference By Investing.com - Investing.com South Africa
Avalyn Pharma Inc Azioni (AVLN) Dati Finanziari
Non sono disponibili dati finanziari per Avalyn Pharma Inc (AVLN). Controlla altri titoli per ulteriori informazioni.
Reddito
Reddito netto
Flusso di cassa
EPS
Avalyn Pharma Inc Azioni (AVLN) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Carroll Jill | Director |
May 01 '26 |
Buy |
18.00 |
277,778 |
5,000,004 |
2,186,562 |
| SR ONE CAPITAL MANAGEMENT, LLC | 10% Owner |
May 01 '26 |
Buy |
18.00 |
555,555 |
9,999,990 |
2,186,562 |
1.27%
1.43%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):